•“Off-the-shelf” genetically modified mouse and rat models to support research in ADMET, Immunology, Metabolic and Genetic disorders are also provided through this agreement. genOway’s customer portfolio already includes 55 bio-pharmaceutical companies; among them are 6 of the world’s leading top 10 pharmaceutical companies.
“This new alliance further demonstrates that the company is viewed as the preferred provider by leading biopharmaceutical companies. In the last 2 years, genOway has signed 7 corporate deals and 3 other multi-million dollar agreements with US-based and European companies and academic research networks”, said Alexandre Fraichard, CEO of genOway.
About genOway
genOway (ALTERNEXT-NYSE:ALGEN) is a biotechnology company dedicated to the development of genetically modified animal models aimed at enhancing the reliability and relevancy of in vivo research projects. Focusing its efforts on the mouse and rat, genOway’s expertise comprises transgenic technologies such as pronuclear microinjection, knock-out, knock-in, knock-down, point mutation and humanization combined with innovative patented technologies adapted to target validation, in vivo drug screening as well as drug efficacy and safety trials. Collaborations with world leaders (Charles River Laboratories, Invitrogen, Tet systems, etc.) enable genOway to provide its customer with a complete portfolio of products and services for all aspects of model generation and characterization. Operating in 22 countries in Europe, North America and Asia, genOway has developed rat and mouse lines for 55 companies and 190 research institutions. Thanks to its industrialized production facilities, genOway is involved in large-scale projects with several academic centers (German National Genome Research Network, University College London, King’s College London, Max Planck Institute) and with pharmaceutical companies.For more information consult: www.genoway.com
